AXIM® Biotechnologies, a world leader in cannabinoid research and development, today announced that it has begun pharmacokinetic/pharmacodynamics studies with its CanChew Plus® Gum, the first CBD hemp oil chewing gum, to determine a reduction of irritable bowel syndrome (IBS) symptoms in patients.
AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has begun pharmacokinetic/pharmacodynamics (PK/PD) studies with its CanChew Plus® Gum, the first CBD hemp oil chewing gum, to determine a reduction of irritable bowel syndrome (IBS) symptoms in patients.
The PK/PD studies are being conducted at the Wageningen University in the Netherlands, the only university in the Country to focus specifically on the theme ‘healthy food and living environment.’ The single dose study on 10 mg of cannabidiol (CBD) and 30 mg of CBD will determine the concentration of CBD in the blood after chewing one CanChew Plus® Gum for thirty minutes, which will determine the administered patient dose for Phase II trials.
“This is another step forward for AXIM in using cannabinoid-based drugs to find answers for health conditions with currently no known sustainable answers,” states George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “IBS is the most common functional gastrointestinal disorder in the world, and it currently has no cure. Our goal is to help people suffering from not only IBS, but a range of disorders that affect people’s gastro-intestinal disorders with no effective remedies such as IBS, IBD and Crohn’ disease.”
The founders and managers of AXIM® Biotech are the inventors of CanChew® which is the world’s first patented controlled-release cannabinoid chewing gum containing 10 mg of CBD procured from the industrial hemp plant. AXIM Biotech holds the exclusive rights to market and distribute CanChew® Gum and CanChew Plus® globally.
CanChew® is a unique hemp-derived CBD functional chewing gum that is distinctly different than any other brands of gum on the market. Features listed on the CanChew® website include:
- Non-habit forming
- No prescription needed
- Available in all 50 states
- Great-tasting mint gum has no artificial sweeteners or preservatives
- Non-GMO, gluten free, vegan and kosher
CanChew Plus® is a vastly improved delivery system than the alpha version of CanChewÒ Gum. It is produced by a leading European functional gum manufacturer.
Featured in Healthy Living Magazine, CanChew® was also recognized by the HealthyLivinG Foundation and honored with its Triple Leaf Award.
AXIM® Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology Company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 888-829-0070 email@example.com www.cmwmedia.com Corporate Contact Info: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227